Mesothelioma Clinical Trials Alimta (pemetrexed) plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma This study is currently recruiting patients. Sponsored by Eli Lilly and Company For more information:National Cancer Institute (NCI) Purpose: This study aims to determine how successful the chemotherapy regimen of Alimta(pemetrexed) plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the cancer returns and if so, where, will also be monitored. Condition Treatment or Intervention Pleural Neoplasms  Drug: Alimta (pemetrexed) and cisplatin This is a Phase III test In Phase III studies, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.  Study Type: Interventional Study Design: Treatment Eligilibty: Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both Criteria Inclusion Criteria: the tumor can be surgically removed no prior treatment, either chemotherapy, surgery, or radiation sign informed consent form Exclusion Criteria: prior use of experimental drug pregnanacy or breast-feeding refusal to have surgery